Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity against Yersinia Infection in Adult and Infant Mice.

Heine SJ, Franco-Mahecha OL, Sears KT, Drachenberg CB, van Roosmalen ML, Leenhouts K, Picking WL, Pasetti MF.

J Immunol. 2019 Apr 1;202(7):2005-2016. doi: 10.4049/jimmunol.1800985. Epub 2019 Feb 20.

PMID:
30787109
2.

A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice.

Wang D, Lu J, Yu J, Hou H, Leenhouts K, Van Roosmalen ML, Gu T, Jiang C, Kong W, Wu Y.

Immunol Invest. 2018 May;47(4):403-415. doi: 10.1080/08820139.2018.1439505. Epub 2018 Mar 2.

PMID:
29498560
3.

Biophysical Characterization of the Type III Secretion System Translocator Proteins and the Translocator Proteins Attached to Bacterium-Like Particles.

Chen X, Choudhari SP, Kumar P, Toth RT 4th, Kim JH, Van Roosmalen ML, Leenhouts K, Middaugh CR, Picking WL, Picking WD.

J Pharm Sci. 2015 Dec;104(12):4065-4073. doi: 10.1002/jps.24659. Epub 2015 Sep 30.

PMID:
26422758
4.

Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice.

Heine SJ, Franco-Mahecha OL, Chen X, Choudhari S, Blackwelder WC, van Roosmalen ML, Leenhouts K, Picking WL, Pasetti MF.

Immunol Cell Biol. 2015 Aug;93(7):641-52. doi: 10.1038/icb.2015.24. Epub 2015 Mar 17.

5.

Biophysical characterization of the type III secretion tip proteins and the tip proteins attached to bacterium-like particles.

Choudhari SP, Chen X, Kim JH, Van Roosmalen ML, Greenwood JC 2nd, Joshi SB, Picking WD, Leenhouts K, Middaugh CR, Picking WL.

J Pharm Sci. 2015 Feb;104(2):424-32. doi: 10.1002/jps.24047. Epub 2014 Jun 10.

6.

Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.

Keijzer C, Haijema BJ, Meijerhof T, Voorn P, de Haan A, Leenhouts K, van Roosmalen ML, van Eden W, Broere F.

Vaccine. 2014 May 19;32(24):2904-10. doi: 10.1016/j.vaccine.2014.02.019. Epub 2014 Mar 2.

7.

An expression system for the efficient incorporation of an expanded set of tryptophan analogues.

Petrović DM, Leenhouts K, van Roosmalen ML, Broos J.

Amino Acids. 2013 May;44(5):1329-36. doi: 10.1007/s00726-013-1467-3. Epub 2013 Feb 13.

PMID:
23404517
8.

Monitoring lysin motif-ligand interactions via tryptophan analog fluorescence spectroscopy.

Petrović DM, Leenhouts K, van Roosmalen ML, Kleinjan F, Broos J.

Anal Biochem. 2012 Sep 15;428(2):111-8. doi: 10.1016/j.ab.2012.06.009. Epub 2012 Jun 17.

PMID:
22713342
9.

Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.

de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.

Vaccine. 2012 Jul 6;30(32):4884-91. doi: 10.1016/j.vaccine.2012.04.032. Epub 2012 Apr 23.

PMID:
22537989
10.

Bacterium-like particles as multi-epitope delivery platform for Plasmodium berghei circumsporozoite protein induce complete protection against malaria in mice.

Nganou-Makamdop K, van Roosmalen ML, Audouy SA, van Gemert GJ, Leenhouts K, Hermsen CC, Sauerwein RW.

Malar J. 2012 Feb 20;11:50. doi: 10.1186/1475-2875-11-50.

11.

Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.

Saluja V, Visser MR, Ter Veer W, van Roosmalen ML, Leenhouts K, Hinrichs WL, Huckriede A, Frijlink HW.

Vaccine. 2010 Nov 23;28(50):7963-9. doi: 10.1016/j.vaccine.2010.09.066. Epub 2010 Oct 12.

PMID:
20946860
12.

Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive enhancer matrix (GEM) particles.

Saluja V, Visser MR, van Roosmalen ML, Leenhouts K, Huckriede A, Hinrichs WL, Frijlink HW.

Eur J Pharm Biopharm. 2010 Nov;76(3):470-4. doi: 10.1016/j.ejpb.2010.08.003. Epub 2010 Aug 16.

PMID:
20719246
13.

Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.

Saluja V, Amorij JP, van Roosmalen ML, Leenhouts K, Huckriede A, Hinrichs WL, Frijlink HW.

AAPS J. 2010 Jun;12(2):109-16. doi: 10.1208/s12248-009-9168-2. Epub 2010 Jan 8.

14.

Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection.

Ramirez K, Ditamo Y, Rodriguez L, Picking WL, van Roosmalen ML, Leenhouts K, Pasetti MF.

Mucosal Immunol. 2010 Mar;3(2):159-71. doi: 10.1038/mi.2009.131. Epub 2009 Nov 18.

15.

Lactococcus lactis as expression host for the biosynthetic incorporation of tryptophan analogues into recombinant proteins.

El Khattabi M, van Roosmalen ML, Jager D, Metselaar H, Permentier H, Leenhouts K, Broos J.

Biochem J. 2008 Jan 1;409(1):193-8.

PMID:
17910535
16.

Development of lactococcal GEM-based pneumococcal vaccines.

Audouy SA, van Selm S, van Roosmalen ML, Post E, Kanninga R, Neef J, Estevão S, Nieuwenhuis EE, Adrian PV, Leenhouts K, Hermans PW.

Vaccine. 2007 Mar 22;25(13):2497-506. Epub 2006 Sep 18.

PMID:
17081660
17.

Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization.

Audouy SA, van Roosmalen ML, Neef J, Kanninga R, Post E, van Deemter M, Metselaar H, van Selm S, Robillard GT, Leenhouts KJ, Hermans PW.

Vaccine. 2006 Jun 29;24(26):5434-41. Epub 2006 Apr 3.

PMID:
16757068
18.

Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria.

van Roosmalen ML, Kanninga R, El Khattabi M, Neef J, Audouy S, Bosma T, Kuipers A, Post E, Steen A, Kok J, Buist G, Kuipers OP, Robillard G, Leenhouts K.

Methods. 2006 Feb;38(2):144-9.

PMID:
16414272
19.

Novel surface display system for proteins on non-genetically modified gram-positive bacteria.

Bosma T, Kanninga R, Neef J, Audouy SA, van Roosmalen ML, Steen A, Buist G, Kok J, Kuipers OP, Robillard G, Leenhouts K.

Appl Environ Microbiol. 2006 Jan;72(1):880-9.

20.

Type I signal peptidases of Gram-positive bacteria.

van Roosmalen ML, Geukens N, Jongbloed JD, Tjalsma H, Dubois JY, Bron S, van Dijl JM, Anné J.

Biochim Biophys Acta. 2004 Nov 11;1694(1-3):279-97. Review.

21.

Distinction between major and minor Bacillus signal peptidases based on phylogenetic and structural criteria.

van Roosmalen ML, Jongbloed JD, Dubois JY, Venema G, Bron S, van Dijl JM.

J Biol Chem. 2001 Jul 6;276(27):25230-5. Epub 2001 Apr 17.

22.

Detergent-independent in vitro activity of a truncated Bacillus signal peptidase.

van Roosmalen ML, Jongbloed JDH, Jong A, van Eerden J, Venema G, Bron S, Maarten van Dijl J.

Microbiology. 2001 Apr;147(Pt 4):909-917. doi: 10.1099/00221287-147-4-909.

PMID:
11283286
23.

A truncated soluble Bacillus signal peptidase produced in Escherichia coli is subject to self-cleavage at its active site.

van Roosmalen ML, Jongbloed JD, Kuipers A, Venema G, Bron S, van DijL JM.

J Bacteriol. 2000 Oct;182(20):5765-70.

24.

SecDF of Bacillus subtilis, a molecular Siamese twin required for the efficient secretion of proteins.

Bolhuis A, Broekhuizen CP, Sorokin A, van Roosmalen ML, Venema G, Bron S, Quax WJ, van Dijl JM.

J Biol Chem. 1998 Aug 14;273(33):21217-24.

25.

Functional analysis of the secretory precursor processing machinery of Bacillus subtilis: identification of a eubacterial homolog of archaeal and eukaryotic signal peptidases.

Tjalsma H, Bolhuis A, van Roosmalen ML, Wiegert T, Schumann W, Broekhuizen CP, Quax WJ, Venema G, Bron S, van Dijl JM.

Genes Dev. 1998 Aug 1;12(15):2318-31.

Supplemental Content

Loading ...
Support Center